

<https://helda.helsinki.fi>

---

## Multiparametric platform for profiling lipid trafficking in human leukocytes

Pfisterer, Simon G.

2022

---

Pfisterer , S G , Brock , I , Kanerva , K , Hlushchenko , I , Paavolainen , L , Ripatti , P , Islam , M M , Kyttälä , A , Di Taranto , M D , Scotto di Frega , A , Fortunato , G , Kuusisto , J , Horvath , P , Ripatti , S , Laakso , M & Ikonen , E 2022 , ' Multiparametric platform for profiling lipid trafficking in human leukocytes ' , Cell Reports Methods , vol. 2 , no. 2 , 100166 . <https://doi.org/10.1016/j.crmeth.2022.100166>

---

<http://hdl.handle.net/10138/352701>

<https://doi.org/10.1016/j.crmeth.2022.100166>

---

cc\_by

publishedVersion

---

*Downloaded from Helda, University of Helsinki institutional repository.*


*This is an electronic reprint of the original article.*

*This reprint may differ from the original in pagination and typographic detail.*

*Please cite the original version.*

# Multiparametric platform for profiling lipid trafficking in human leukocytes

## Graphical abstract



## Authors

Simon G. Pfisterer, Ivonne Brock, Kristiina Kanerva, ..., Samuli Ripatti, Markku Laakso, Elina Ikonen

## Correspondence

simon.pfisterer@helsinki.fi (S.G.P.), elina.ikonen@helsinki.fi (E.I.)

## In brief

Insights into cellular dysfunction underlying hypercholesterolemia are lacking. Pfisterer et al. establish an automated analysis platform enabling quantification of multiple cellular readouts, including lipid uptake, storage, and mobilization, from different white blood cell populations. This approach provides personalized insights into the cellular basis of hypercholesterolemia and obesity.

## Highlights

- High-content imaging platform for quantification of low-density lipoprotein uptake
- Quantifies lipid storage and mobilization in cytoplasmic droplets of primary leukocytes
- Approach provides personalized insights into cellular basis of hypercholesterolemia
- Combining functional and polygenic scores improves hypercholesterolemia risk assessment



## Article

# Multiparametric platform for profiling lipid trafficking in human leukocytes

Simon G. Pfisterer,<sup>1,12,\*</sup> Ivonne Brock,<sup>1,2,3</sup> Kristiina Kanerva,<sup>1,2,3</sup> Iryna Hlushchenko,<sup>1</sup> Lassi Paavolainen,<sup>4</sup> Pietari Ripatti,<sup>4</sup> Mohammad Majharul Islam,<sup>1</sup> Aija Kyttälä,<sup>5</sup> Maria D. Di Taranto,<sup>6,7</sup> Annalisa Scotto di Frega,<sup>7</sup> Giuliana Fortunato,<sup>6,7</sup> Johanna Kuusisto,<sup>8</sup> Peter Horvath,<sup>4,9</sup> Samuli Ripatti,<sup>4,10,11</sup> Markku Laakso,<sup>8</sup> and Elina Ikonen<sup>1,2,3,\*</sup>

<sup>1</sup>Department of Anatomy, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland

<sup>2</sup>Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland

<sup>3</sup>Minerva Foundation Institute for Medical Research, Helsinki, Finland

<sup>4</sup>Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

<sup>5</sup>Finnish Institute for Health and Welfare (THL), THL Biobank, Helsinki, Finland

<sup>6</sup>Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Napoli, Italy

<sup>7</sup>CEINGE Biotechnologie Avanzate scrl Napoli, Napoli, Italy

<sup>8</sup>Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland

<sup>9</sup>Biological Research Center, Szeged, Hungary

<sup>10</sup>Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland

<sup>11</sup>The Broad Institute of MIT and Harvard, Cambridge, MA, USA

<sup>12</sup>Lead contact

\*Correspondence: [simon.pfisterer@helsinki.fi](mailto:simon.pfisterer@helsinki.fi) (S.G.P.), [elina.ikonen@helsinki.fi](mailto:elina.ikonen@helsinki.fi) (E.I.)

<https://doi.org/10.1016/j.crmeth.2022.100166>

**MOTIVATION** We have limited information on how cellular lipid uptake and processing differ between individuals and influence the development of metabolic diseases, such as hypercholesterolemia. Available assays are labor intensive, require skilled personnel, and are difficult to scale to higher throughput, making it challenging to obtain systematic, functional cell-based data from individuals. To overcome this problem, we established a scalable automated analysis pipeline enabling reliable quantification of multiple cellular readouts, including lipid uptake, storage, and mobilization, from different white blood cell populations. This approach provides personalized insights into the cellular basis of hypercholesterolemia and obesity.

## SUMMARY

Systematic insight into cellular dysfunction can improve understanding of disease etiology, risk assessment, and patient stratification. We present a multiparametric high-content imaging platform enabling quantification of low-density lipoprotein (LDL) uptake and lipid storage in cytoplasmic droplets of primary leukocyte subpopulations. We validate this platform with samples from 65 individuals with variable blood LDL-cholesterol (LDL-c) levels, including familial hypercholesterolemia (FH) and non-FH subjects. We integrate lipid storage data into another readout parameter, lipid mobilization, measuring the efficiency with which cells deplete lipid reservoirs. Lipid mobilization correlates positively with LDL uptake and negatively with hypercholesterolemia and age, improving differentiation of individuals with normal and elevated LDL-c. Moreover, combination of cell-based readouts with a polygenic risk score for LDL-c explains hypercholesterolemia better than the genetic risk score alone. This platform provides functional insights into cellular lipid trafficking and has broad possible applications in dissecting the cellular basis of metabolic disorders.


## INTRODUCTION

Hypercholesterolemia is one of the most common metabolic disorders and a major risk factor for cardiovascular disease (CVD). It is characterized by an accumulation of low-density lipoprotein cholesterol (LDL-c) in the blood (Borén et al., 2020). In familial hypercholesterolemia (FH), mutations, most commonly in the LDL receptor (*LDLR*) gene, lead to increased LDL-c. However, FH

represents only 2.5% of all hypercholesterolemia patients. For the remainder, polygenic and lifestyle effects appear as the main contributing factors (Abul-Husn et al., 2016; Khera et al., 2016; Ripatti et al., 2020; Talmud et al., 2013).

So far, we have little information on how cellular lipid trafficking and storage are altered in individual patients. However, systematic assessment of LDL uptake and other mechanisms related to hypercholesterolemia could provide insights into disease





**Figure 1. Automated analysis pipeline for multiplex quantification of functional phenotypes in PBMCs**

(A) Schematic presentation of the automated analysis pipeline. For each experiment, cryopreserved PBMC samples were thawed, aliquoted into 96 wells, and incubated overnight with lipid-rich (CM) (10% FBS) or lipid-poor (LP) (5% lipoprotein-deficient serum [LPDS]) medium. Cells were labeled with fluorescent LDL (Dil-LDL) or directly transferred to 384-well imaging plates, automatically fixed, stained, and subjected to automated high-content imaging. Images were quantified with CellProfiler, and single-cell data were processed with Python tools.

(B) Representative images of lymphocyte and monocyte Dil-LDL uptake after lipid starvation.

(C and D) Histogram for cellular Dil-LDL intensities in lymphocytes (C) and monocytes (D) from a single well.

(legend continued on next page)

mechanisms and treatment outcomes in a personalized manner. The majority of high-risk hypercholesterolemia patients do not achieve their LDL-c target levels (Ray et al., 2020). This could be due to sub-optimal treatment, non-adherence to therapy, and/or cellular programs limiting drug efficacy. Increased evidence from cancer therapy demonstrates that cell-based assays can provide better targeted and more effective personalized treatment strategies (Snijder et al., 2017). Regarding hypercholesterolemia, we need to establish scalable and reliable assays that allow systematic profiling of functional defects in individual persons and evaluate how to utilize such assays to better explain factors contributing to hypercholesterolemia in individual patients.

The currently used cell-based assays for studying the etiology of hypercholesterolemia are quantification of cellular LDL uptake or LDLR cell surface expression using flow cytometry. These readouts have been mostly utilized to characterize the severity of *LDLR* mutations in FH patients (Benito-Vicente et al., 2018; Romano et al., 2010). However, LDLR surface expression and LDL uptake are highly variable among FH patients (Tada et al., 2009; Thedrez et al., 2018; Urdal et al., 1997). This not only speaks for the importance of functional cell-based assays but also calls for additional cellular readouts to better characterize the heterogeneity of lipid metabolism in individual subjects.

LDLR expression and cellular LDL internalization are tightly regulated. Low cholesterol levels in the endoplasmic reticulum (ER) signal cholesterol starvation and trigger increased LDLR expression, while high cholesterol in the ER downregulates LDLR expression. Excess ER cholesterol is stored as cholesterol ester in lipid droplets (LDs), from where it can be mobilized upon need (Ikonen, 2008; Luo et al., 2020). We therefore considered that quantification of cellular LDs and their dynamic changes upon altering lipoprotein availability may provide additional information for assessing the cellular basis of hypercholesterolemia.

Here, we established sensitive and scalable analyses for automated quantification of fluorescent lipid uptake, storage, and removal in primary lymphocyte and monocyte populations and defined lipid mobilization as an additional parameter measuring how efficiently cells deplete their lipid stores. We found marked differences in the parameters established in both FH and non-FH study groups and highlight their potential to provide deeper insights into the cellular mechanisms of hypercholesterolemia.

## RESULTS

### Automated pipeline for quantification of hypercholesterolemia-related functional defects in primary human leukocytes

Several cell types, such as lymphocytes, monocytes, and Epstein-Barr virus (EBV) immortalized lymphoblasts, have been used for measuring LDL uptake (Chan et al., 1997; Schmitz

et al., 1993). While EBV lymphoblasts show the highest LDL uptake, cell immortalization is time consuming and alters cellular functions (Chan et al., 1997; Piccaluga et al., 2018). We therefore set up an automated imaging and analysis pipeline for sensitive quantification of LDL uptake and LDLR surface expression from less than two million peripheral blood mononuclear cells (PBMCs) (Figure 1A). Cryopreserved PBMCs were recovered in 96-well plates at defined densities and incubated with lipid-rich control medium (CM) (10% fetal bovine serum [FBS]) or lipid poor medium (LP) (5% lipoprotein-deficient serum) for 24 h. Cells were labeled with fluorescent LDL particles (Dil-LDL) for 1 h, washed, and automatically transferred to 384-well plates for staining and automated high-content imaging (Figure 1A). After adhesion to coated imaging plates, lymphocytes remain small while monocytes spread out, enabling a crude classification of leukocyte populations based on size: PBMCs with a cytoplasmic area  $<115 \mu\text{m}^2$  were classified as a lymphocyte-enriched fraction (from here on lymphocytes) and those with a cytoplasmic area  $>115 \mu\text{m}^2$  as monocyte-enriched fraction (from here on monocytes; Figures S1A–S1C).

In CM, Dil-LDL uptake into lymphocytes and monocytes was more than 2-fold above the background of non-labeled cells (Figures 1B–1D). Lipid starvation further increased Dil-LDL uptake in both cell populations, as expected (Figures 1C and 1D). We quantified about 700 monocytes and 2,300 lymphocytes per well (Figure S1D), aggregated the single-cell data from individual wells, and averaged the results from 2–4 wells for each treatment (Figure S1D). For both cell populations, we defined 2 readouts: cellular Dil-LDL intensity (Dil-Int), reflecting Dil-LDL surface binding and internalization, and Dil-LDL organelle number (Dil-No), reflecting internalized Dil-LDL (Figures 1E and 1F). This resulted in 4 parameters: monocyte (Mo) Dil-Int, lymphocyte (Ly) Dil-Int, Mo Dil-No, and Ly Dil-No. In both cell populations, Dil-Int was inhibited by adding surplus unlabeled LDL, arguing for a saturable, receptor-mediated uptake mechanism (Figure S1E).


In lipid-rich conditions, Mo Dil-Int was slightly higher than Ly Dil-Int (Figure 1E), and upon lipid starvation, Mo Dil-Int increased more substantially, providing a larger fold increase than Ly Dil-Int (Figure 1E). Furthermore, Mo Dil-No was roughly 10-fold higher than Ly Dil-No, with both parameters showing a 5-fold increase upon lipid starvation (Figure 1F). Thus, Dil-LDL uptake into monocytes was better than into lymphocytes, but both cell populations responded to lipid starvation. As EBV lymphoblasts are often a preferred choice for LDL uptake studies (Chan et al., 1997), we compared LDL uptake between EBV lymphoblasts and monocytes (Figures S1F and S1G). This showed that Dil-Int signal after lipid starvation was roughly similar in EBV lymphoblasts and monocytes, implying that the primary cells provide high enough Dil-LDL signal intensities without cell immortalization (Figure S1G).

(E and F) Quantification of mean Dil-LDL intensities (E) and Dil-LDL organelles (F) in lymphocytes (Ly) and monocytes (Mo); representative of 8 independent experiments, each with 4 wells per treatment; Student's *t* test.

(G) Representative images of Dil-LDL uptake in monocytes isolated from FH patients with LDLR mutations Cys325Tyr or Ser580Phe and a control after lipid starvation.

(H) Quantification of monocyte (Mo) and lymphocyte (Ly) cellular Dil-LDL intensities (Int.), Dil-LDL organelle numbers (No.), and pan-uptake; duplicate wells/patient (8 wells/patient for pan-uptake). Significant changes to control 2 were calculated with Welch's *t* test.

\*\*\**p* < 0.001 and \*\**p* < 0.01; scale bars represent 10  $\mu\text{m}$ ; error bars represent SEM.



**Figure 2. Heterogeneous LDL uptake and LDLR surface expression in He-FH patients' monocytes**

(A) Schematic presentation of LDLR mutations included in this study together with their pathogenicity status from ClinVar and LOVD databases indicated in bold (LB, likely benign; LP, likely pathogenic; P, pathogenic; VUS, variant of unknown significance).

(B) Quantification of monocyte (Mo) and lymphocyte (Ly) cellular Dil-LDL intensities (Int.), organelle numbers (No.), and pan-uptake normalized to 2 controls (100%); 2 to 3 independent experiments, each with duplicate or quadruplicate wells per patient (8–16 wells per patient for pan-uptake). Cys325Tyr and Ser580Phe were described in Figures 1G and 1H. Significant changes to control two were calculated with Welch's t test.

(legend continued on next page)

To enable data comparison between experiments, we included 2 controls. Each control consisted of a mixture of large-scale PBMC isolations from 4 healthy blood donors, with the cells cryopreserved at a defined density for one-time-use aliquots. In each experiment, Mo Dil-Int, Ly Dil-Int, Mo Dil-No, and Ly Dil-No were normalized to these controls. We also introduced a combinatorial score, pan-LDL uptake (or pan-uptake), representing the average of Mo Dil-Int, Ly Dil-Int, Mo Dil-No, and Ly Dil-No. We then assessed the intraindividual variability of these 5 readouts in 3 individuals on 2 consecutive days (Figure S1H). The intraindividual variability was low for a cell-based assay, especially in monocytes, with 7.6% for Mo Dil-No, 12% for Mo Dil-Int, and 13% for pan-uptake. The values were only moderately higher in lymphocytes, with Dil-Int 15% and Dil-No 21% variability (Figure S1I).

We next validated our LDL uptake measurements in PBMCs of 2 He-FH patients with highly elevated LDL-c and reduced LDL uptake in EBV lymphoblasts (Cys325Tyr and Ser580Phe mutations in *LDLR*; Figure S1J). For both patients, Mo and Ly Dil-No as well as Mo Dil-Int were reduced by more than 45%, Ly Dil-Int was less profoundly decreased, and pan-uptake was reduced by over 50% (Figures 1G, 1H, and S1J). Together, these data indicate that our analysis pipeline enables quantification of multiple LDL uptake parameters in major leukocyte cell populations and distinguishes defective LDLR function therein.

### Heterogeneous LDL uptake and LDLR surface expression in He-FH patients

We next used this pipeline to characterize 21 He-FH patients from the metabolic syndrome in men (METSIM) cohort study (Laakso et al., 2017; Table S1). The patients' mutations reside in the *LDLR* coding region and range from pathogenic to likely benign variants (Figure 2A). Quantification of Dil-Int and Dil-No for monocytes and lymphocytes provided relatively similar results for each individual (Figure 2B). However, there were substantial differences in these parameters between individuals, including patients harboring identical *LDLR* mutations (Figure 2B). This was most pronounced for FH-North Karelia (Pro309Lysfs\*59), a pathogenic loss-of-function variant but also evident for FH-Pogosta (Arg595Gln) and FH-Glu626Lys (Figures 2A and 2B). These observations imply that, in He-FH, regulatory mechanisms may enhance the expression of the unaffected *LDLR* allele and/or stabilize the encoded protein. In support of this notion, we obtained a strong correlation between monocyte LDLR surface expression and Dil-Int, Dil-No, and pan-uptake scores for the same individuals (pan-uptake;  $R = 0.58$ ;  $p = 0.006$ ; Figures 2C and S2A).

Interestingly, the pan-uptake score showed a tendency for lower values in FH-North Karelia carriers as compared with those carrying the likely pathogenic FH-Pogosta and likely benign Glu626Lys variants (Figure S2B). This is in agreement with higher LDL-c concentrations in FH-North Karelia patients (Lahtinen

et al., 2015). While LDL uptake did not correlate with circulating LDL-c for the entire study group (Figure S2C), this correlation was highly significant for monocyte Dil-Int, Dil-No, and the pan-uptake scores for the 11 He-FH patients on statin monotherapy (Mo Dil-Int:  $R = -0.75$ ;  $p = 0.0081$ ; Figure 2D). Notably, three of the individuals with the lowest monocyte Dil-Int had a 2-fold higher LDL-c concentration than the 3 individuals with the highest monocyte Dil-Int; Figure 2E), suggesting that the LDL-c-lowering effect of statin is reflected by monocyte LDL uptake. This is likely due to the higher LDL uptake capacity of monocytes as compared with lymphocytes (Figures 1E and 1F).

### LDL uptake in non-FH individuals with normal or elevated circulating LDL-c

As most hypercholesterolemia patients do not carry *LDLR* mutations, we also investigated cellular LDL uptake in PBMCs from 20 biobank donors with elevated LDL-c levels (LDL-c > 5 mM) (hLDL-c) and from 19 donors with normal LDL levels (LDL-c 2–2.5 mM) (nLDL-c) from the FINRISK population cohort (Borodulin et al., 2018; Table S2). DNA sequencing confirmed that common Finnish *LDLR* variants were not present among these subjects.

We quantified Dil-Int and Dil-No for monocyte and lymphocyte populations as well as the pan-uptake score for nLDL-c and hLDL-c individuals. This revealed a large interindividual variation in LDL uptake (Figure 3A). Both groups included persons with severely reduced LDL internalization, although the lowest pan-LDL uptake scores were among the hLDL-c individuals (Figure 3A). Overall, pan-uptake and Ly Dil-No were reduced in hLDL-c compared with nLDL-c subjects, but the differences were not significant (Figures S3A and S3B). Of note, reduced pan-uptake, Mo Dil-Int, and Ly Dil-No correlated with increased serum LDL-c levels in the hLDL-c subgroup, but the correlations relied on a single individual with a very high serum LDL-c concentration (pan-uptake:  $R = -0.49$ ;  $p = 0.028$ ; Figure S3C).

To investigate additional factors influencing the interindividual variability in cellular LDL uptake, we analyzed correlations to 2 obesity indicators: body mass index (BMI) and waist circumference. Strikingly, reduced pan-uptake, as well as Mo Dil-Int and Ly Dil-Int, correlated with increased waist circumference (pan-uptake:  $R = -0.42$ ;  $p = 0.009$ ; Figure 3B). Lower pan-uptake, Ly Dil-Int, and Mo Dil-Int also correlated with elevated BMI (pan-uptake:  $R = -0.36$ ;  $p = 0.022$ ; Figure 3C).

### Assessment of cellular lipid storage and mobilization in leukocytes


Cells store excess lipids in LDs, and this is related to lipid uptake: when peripheral cells have sufficient lipids available, they typically exhibit LDs and, in parallel, lipid uptake is downregulated. We therefore also included the staining of LDs in the automated analysis pipeline (Figure 1A). Staining of PBMCs in lipid-rich conditions (CM) with the well-established LD dye LD540 (Spandl et al., 2009) revealed that lymphocytes and monocytes

(C) Correlation of pan-uptake and monocyte LDLR surface expression, including R and p values for all uptake scores;  $n = 21$  patients.

(D) Correlation of monocyte Dil-LDL intensities (Mo Int) with circulating LDL-c for heterozygous FH patients on statin monotherapy, including R and p values for all uptake scores.

(E) LDL-c concentration for 3 patients with the highest (high) and lowest (low) monocyte mean Dil-LDL intensity (Mo Int) as in (D).

Gray areas in scatter plots indicate 95% confidence interval (CI); \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$ . Error bars represent SEM



**Figure 3. LDL uptake profiles in non-FH individuals with normal and elevated LDL-c**

(A) Quantification of monocyte (Mo) and lymphocyte (Ly) mean DiI-LDL intensities (Int.), organelle numbers (No.), and pan-uptake after lipid starvation, normalized to control standards; duplicate wells per patient (8 wells per patient for pan-uptake). Significant changes to control two were calculated with Welch's t test. (B and C) Correlation of pan-uptake (B) with waist circumference and (C) with body mass index (BMI), including R and p values for all uptake scores.  $n = 39$ . Gray areas in scatter plots indicate 95% CI. \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$ . Error bars represent SEM

displayed LDs in a heterogenous fashion (Figure 4A), with lymphocytes showing fewer LD-positive cells and fewer LDs per cell than monocytes (Figures 4B and 4C). We then visualized the changes in LD abundance upon overnight lipid starvation in lipoprotein-deficient medium (LP; Figures 4B–4F). This resulted in a pronounced decrease in lipid deposition: in CM, 9% of lymphocytes and 25% of monocytes contained LDs, but upon lipid starvation, these were reduced to 6% (Ly) and 12% (Mo; Figure 4D).

Due to the lower LD abundance in lymphocytes, we focused on monocytes and defined 3 readouts for them: (1) percentage of LD-positive cells (LD-Pos), (2) cellular LD number in LD-Pos (LD-No), and (3) total cellular LD area in LD-Pos (LD-Area). On average, LD-Pos cells showed 2.9 LDs in lipid-rich conditions and 1.8 LDs upon lipid starvation (Figure 4E), while the total LD area decreased from  $1.35 \mu\text{m}^2$  in lipid-rich conditions to  $0.8 \mu\text{m}^2$  upon lipid starvation (Figure 4F).

When quantifying LD parameters from several subjects, we observed substantial differences between individuals in how LDs changed upon starvation. To systematically quantify these differences, we established a parameter, lipid mobilization score that reflects how efficiently cellular lipid stores are depleted under lipid starvation (Figure 4G). Lipid mobilization scores were


calculated for each of the LD readouts, LD-Pos, LD-No, and LD-Area, by dividing the results obtained in lipid-rich conditions with those obtained after lipid starvation (Figure 4G). Furthermore, we established a pan-mobilization score by averaging LD-Pos, LD-No, and LD-Area scores (Figures 4G and 4H), with LD-Pos providing the highest mobilization score but also the highest variability (Figure 4H).

To further assess the reliability of the LD mobilization parameters, we determined their intraindividual variation using the same samples as for analyzing intraindividual variation of DiI-LDL uptake (Figures S1I and S1J). This showed a modest intraindividual variation for the lipid mobilization scores (Figure S4A), with an average of 8% for pan-mobilization, 10% for LD-Pos, 11% for LD-No, and 13% for LD-Area (Figure S4B).

### Cellular lipid mobilization in He-FH patients

When lipid mobilization was analyzed from the He-FH samples of the METSIM cohort, we found that the pan-mobilization score was significantly reduced in He-FH individuals carrying the FH-North Karelia and Glu626Lys variants (Figure 4I). This suggests that defective LDLR function may be accompanied by reduced lipid mobilization. We also studied whether the combination of a lipid mobilization score with LDL uptake improves identification





**Figure 4. Lipid mobilization assay**

(A) Representative images showing lipid droplets (LDs) in lymphocyte and monocyte populations after treatment with control medium; scale bars represent 10  $\mu\text{m}$ .

(B and C) Histogram for cellular LD counts in (B) lymphocyte and (C) monocyte populations after treatment with control medium (CM) and lipid starvation (LP) from a single well.

(D) Quantification of LD-positive cells in Lys and Mos upon treatment with CM and LP; representative of 3 independent experiments, each with duplicate wells per patient and treatment.

(E and F) LD counts (E) and total LD area (F) in LD-positive monocytes quantified for the same experiment as in (D).

(G) Schematic presentation of the lipid mobilization score. Upon lipid starvation, the fraction of LD-positive monocytes (LD-Pos), their total LD area (LD-Area), and LD numbers (LD-No) are decreasing. Mobilization scores are calculated by dividing the amount of LD-Pos, LD-No, or LD-Area in CM with the respective quantifications after lipid starvation. Pan-mobilization is the average of LD-Pos, LD-No, and LD-Area mobilization scores from individual wells.

(H) Lipid mobilization scores for 1 control;  $n = 6$  wells from 3 independent experiments (18 wells for pan-mobilization)  $\pm$  SEM.

(legend continued on next page)

of statin recipients with high residual LDL-c concentrations. Several of the patients with intermediate and high LDL-c showed low monocyte DiI-LDL intensities in a narrow range (Figure 2D). When monocyte DiI-Int was combined with the pan-mobilization score, larger differences between patients were observed, providing a better separation of individuals with high and intermediate LDL-c (Figure 4J). Moreover, the difference in LDL-c concentration between the 3 individuals with the highest versus lowest score was more significant than when using monocyte DiI-Int alone (Figure 4K versus Figure 2E). This suggests that the combined LDL uptake and lipid mobilization assays may help to better pinpoint those He-FH cases that remain refractory to statin monotherapy.

### Cellular lipid mobilization is reduced in non-FH patients and correlates with LDL uptake

We then investigated whether monocytes from nLDL-c and hLDL-c biobank donors displayed differences in lipid mobilization. Analogously to LDL uptake, we observed a large variability for the pan- and individual mobilization scores in this cohort (Figure 5A). Interestingly, pan-mobilization, LD-No, and LD-Area were significantly reduced in the hLDL-c compared with nLDL-c subjects (Figures 5A, 5B, S5A, and S5B). This prompted us to scrutinize whether lipid mobilization correlates with LDL-uptake-related parameters in this cohort. All mobilization scores correlated positively with the pan-uptake score ( $R = 0.42$ ;  $p = 0.0095$  for pan-mobilization; Figure 5C). Furthermore, pan-, LD-No, and LD-Area mobilization scores correlated negatively with total cholesterol, apo-B concentrations (Figures S5C and S5D), and with age ( $R = -0.38$ ,  $p = 0.019$  for pan-mobilization; Figure 5D).

### Hybrid scores of genetic and functional cell-based data show improved association with hypercholesterolemia

The hLDL-c biobank donors of the FINRISK population cohort displayed an increased LDL-c polygenic risk score (LDL-PRS) (Figure 6A). LDL-PRS did not correlate with LDL uptake or lipid mobilization (Figures S6A and S6B), suggesting that LDL-PRS and cellular LDL uptake monitor, in part, distinct processes. Interestingly, combination of LDL-PRS with pan-uptake reduced the variation and made it easier to discriminate the nLDL-c and hLDL-c groups, providing an 8-times-better  $p$  value as compared with LDL-PRS only (Figure 6B). Furthermore, combination of the pan-mobilization score with LDL-PRS drastically improved the discrimination between groups (Figure 6C), and combining all 3 parameters, i.e., LDL-PRS, pan-uptake, and pan-mobilization, provided the best discrimination power and lowest  $p$  value (Figure 6D). To further highlight the benefits of combining genetic and functional cell data, we calculated the odds ratio (OR) for elevated LDL-c by comparing individuals with the highest 30% of the scores to the remaining subjects. Interestingly, combining LDL-PRS with either pan-uptake or pan-mobilization doubled the

OR, and using a hybrid score combining all 3 readouts resulted in a 5-fold higher OR (Figure 6E). The odds for having elevated LDL-c was 21 times higher for a person within the highest 30% of the triple hybrid score, as compared with the remaining subjects, highlighting the strength of functional hybrid scores. This is further supported by calculating the OR for 25%, 30%, 35%, and 40% of the individuals with the highest LDL-PRS, double or triple hybrid scores, and the remaining subjects, which in almost all instances provided higher OR for hybrid scores than for LDL-PRS (Figure S6C).

## DISCUSSION

In this study, we established a multiplexed analysis pipeline to quantify lipid uptake and mobilization in primary leukocytes and used it to analyze over 300 conditions (combinations of assays and treatments) from 65 individuals. The automated cell handling, staining, and imaging procedures enable high-throughput applications. Key advantages of the method are (1) large-scale internal standards allow comparison of experimental results over time; (2) automated cell quantification avoids researcher bias, increasing reliability of results; (3) semi-automated workflow can be scaled to increase throughput; (4) cell immobilization on coated surfaces allows flexibility in sample handling and facilitates automation, (5) lymphocyte- and monocyte-enriched cell populations can be detected based on cell spreading on coated surfaces; and (6) subcellular resolution enables quantification of internalized LDL and LDs, yielding additional scores derived from them. In conventional flow cytometry assays, cells are quantified when passing through a capillary, providing mean cellular intensities without subcellular resolution. The cells need to be in suspension, and cell aggregation can obstruct the capillary. This complicates cell handling and requires centrifugation steps for cell washing, making it more challenging to automate the assays. Consequently, the first two aspects can be readily included in flow cytometry assays while the latter four rely on a high-content, high-resolution imaging platform.


Several of the observations made using this analysis pipeline are supported by previous findings obtained using manual assays, thereby validating our results. We showed that monocytes display higher LDL uptake activities than lymphocytes, in accordance with previous findings (Schmitz et al., 1993). The highly variable LDL uptake observed by us between individuals, including He-FH patients with identical *LDLR* mutations, also agrees with earlier reports (Tada et al., 2009; Thedrez et al., 2018; Urdal et al., 1997). Furthermore, we observed an association of low cellular LDL uptake with increased circulating LDL-c in He-FH patients on statin monotherapy, in line with studies utilizing radiolabeled LDL (Gaddi et al., 1991; Hagemenas and Illingworth, 1989; Hagemenas et al., 1990; Sun et al., 1998). However, this finding was not readily reproduced by using

(I) Pan-mobilization for controls (combined control one and two from 5 experiments), FH-North-Karelia ( $n = 7$ ), FH-Pogosta ( $n = 3$ ), and FH-Glu626 ( $n = 5$ ).

(J) Correlation of combined monocyte mean DiI-LDL intensities (Mo Int) and pan-mobilization with circulating LDL-c.

(K) LDL-c concentration for 3 patients with the highest (high) and lowest (low) combined score as in (J).

\* $p < 0.05$  and \*\* $p < 0.01$ . Error bars represent SEM.



**Figure 5. Monocyte lipid mobilization correlates with LDL uptake and is reduced in subjects with elevated LDL-c**

(A) Mobilization scores (Pos, LD-No, LD-Area, and pan-mobilization) in monocytes from controls (nLDL-c, LDL-c 2–2.5 mmol/L) and individuals with elevated LDL-c (hLDL-c, LDL >5 mmol/L) sorted according to the pan-uptake score (Figure 3A); duplicate wells per patient (6 wells per patient for pan-mobilization). Significant changes to control two were quantified with Welch's t test.

(B) Box plot of pan-mobilization for nLDL-c and hLDL-c subgroups; nLDL-c n = 19, hLDL-c n = 19. \*\*p < 0.01, Student's t test.

(C and D) Correlation of pan-mobilization with pan-uptake (C) and age (D), including R and p values for all mobilization scores. Gray areas in scatterplots indicate 95% CI. \*p < 0.05, \*-p < 0.01, and \*-p < 0.001. Error bars represent SEM.


fluorescently labeled LDL particles in lymphocytes (Homma et al., 2015; Raungaard et al., 2000). Indeed, our results indicate that monocytes provide an improved detection window and a better correlation between cellular LDL uptake and circulating LDL-c.

We also found that reduced LDL uptake correlated with increased BMI and waist circumference, two obesity indicators. Metabolic syndrome is typically linked to dyslipidemia characterized by decreased high-density lipoprotein cholesterol (HDL-c), elevated LDL-c with increased small, dense LDL particles, and increased plasma triglycerides (Klop et al., 2013). Our results suggest that, besides VLDL overproduction and defective lipolysis of triglyceride (TG)-rich lipoproteins (Borén et al., 2020), reduced LDL clearance may contribute to dyslipidemia in overweight individuals. This fits with the observed reduction of LDLR expression in obese subjects (Mamo et al., 2001).

Moreover, we employed the platform to quantify cellular LDLs, established a parameter termed lipid mobilization score, and demonstrated its ability to provide additional data on individual differences on lipid handling. Lipid mobilization correlated with LDL uptake, implying that efficient removal of stored lipids was typically paralleled by efficient lipid uptake. Moreover, combining monocyte LDL uptake and lipid mobilization data facilitated the detection of He-FH cases that remained hypercholesterolemic

on statin. In the FINRISK population cohort, lipid mobilization outperformed LDL uptake in distinguishing individuals with high (>5 mmol/L) and normal LDL-c (2–2.5 mmol/L), with impaired lipid mobilization associating with elevated LDL-c. Hence, lipid mobilization shows potential to highlight additional aspects of cellular lipid metabolism underlying hypercholesterolemia in individual patients.

Polygenic risk scores (PRSs) provide tools for cardiovascular risk profiling and are increasingly included in clinical care guidelines of hypercholesterolemia (Borén et al., 2020; Mach et al., 2019). We found that the hypercholesterolemia subjects of the FINRISK cohort had an increased LDL-PRS, but this did not correlate with LDL uptake or lipid mobilization, arguing that the cell-based parameters cover in part different territories than PRS. In agreement, the combination of LDL uptake, lipid mobilization, and LDL-PRS improved the segregation of hyper- and normocholesterolemic subjects. An increased LDL-PRS is associated with a higher incidence of coronary artery disease (Ripatti et al., 2020). We therefore anticipate that the cell-based assays may provide additional information for future integrated CVD risk calculations. These, in turn, might facilitate the detection of hypercholesterolemia risk at younger age when clinical manifestations are not yet overt, enabling faster initiation of treatment and improved disease prevention (Wiegman et al., 2015).



**Figure 6. Hybrid scores combining genetic and functional cell-based data show improved association with hypercholesterolemia**

(A) Box plot of a polygenic risk score for high LDL-c levels (LDL-PRS) for nLDL-c (2–2.5 mmol/L LDL-c) and hLDL-c (>5 mmol/L LDL-c) subgroups.

(B and C) Boxplot for double hybrid scores combining LDL-PRS and (B) pan-uptake or pan-mobilization (C) into a single score.

(D) Boxplot for a triple hybrid score consisting of LDL-PRS, pan-uptake, and mobilization.

(E) Odds ratio (OR) for 30% of the individuals with the highest LDL-PRS, double or triple hybrid scores, and the remaining subjects, calculated with the Fisher's exact probability test;  $n = 36$ . The OR for genetic and the hybrid scores are above one, indicating that a person with a high score is more likely to have elevated LDL-c. The significance tests evaluate the likelihood that an OR different from 1 has been obtained by chance. For the combination of LDL-PRS with the functional cell data, this likelihood is very low and our results are significant, while for LDL-PRS alone, this is not the case.

nLDL-c  $n = 18$  and hLDL-c  $n = 18$ ; \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$ ; Welch's t test.

In summary, the automated analysis platform established here enables systematic assessment of cellular lipid trafficking in accessible primary cell samples of human origin. Besides hypercholesterolemia, this approach can be useful in other metabolic disorders, as well as diseases not previously linked to cellular lipid imbalance. As an example of the latter, we recently uncovered aberrant LD size distribution in MYH9-related disease patient neutrophils using quantitative imaging (Pfisterer et al., 2017).

#### Limitations of the study

We analyzed 65 individuals as a proof of concept for the analysis platform. While this outperforms most previous studies measuring lipid uptake in primary cells, further validation in larger study groups will be required to assess its potential clinical utility. Such studies will be feasible due to the high automation level of the platform, enabling processing of samples from several thousand subjects per year. In particular, the finding that combined

LDL uptake and lipid mobilization assays may improve the detection of He-FH cases that remain refractory to statin monotherapy relies on the small number of such individuals in the current study and awaits validation with additional He-FH patients on cholesterol-lowering medication.

Regarding the cellular origin of hypercholesterolemia, we infer parameters related to whole-body metabolism and in particular liver function from PBMCs. Evidently, primary hepatocytes would provide more direct information but are not accessible on a routine basis. PBMCs are easily obtained from standard blood collections. Moreover, our data demonstrate that PBMC-derived parameters can correlate with readouts deriving from the whole body level.

Currently, the analysis platform is set up to quantify two cellular parameters: LDL uptake and lipid storage in droplets. In the present conditions with minimally modified cells, only a fraction of cells (9% of lymphocytes and 25% of monocytes)

contained LDs. Further extensions of the assay can be envisaged, for example, by employing exogenous lipid loading to induce LDs with a specific content prior to lipid mobilization. In the future, the utility of the platform can also be further extended by the inclusion of additional fluorescence-based readouts amenable to high-content imaging and quantification.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Human subject samples
  - Cell lines
- **METHOD DETAILS**
  - PBMC isolation
  - Cell treatments, Dil-LDL uptake, transfer to imaging plates and fixation
  - Lipid droplet analyses
  - LDLR surface staining
  - Quantification of Dil-LDL uptake
  - LDL-c polygenic risk score (LDL-PRS)
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.crmeth.2022.100166>.

### ACKNOWLEDGMENTS

We thank Anna Uro for technical assistance, HiLIFE- and Biocenter-Finland-supported Helsinki Biolmaging infrastructures for help with microscopy, Katarina Öörni for help with LDL preparation, and Abel Szkalitsy for help with image analysis. We thank THL Biobank for providing samples and data for this study (study nos. 2016\_15, 2016\_117, and 2018\_15) and all biobank donors for their participation in biobank research. This study was supported by The Academy of Finland (grants 282192, 284667, and 307415 to E.I.; 321428 to M.L.; 310552 to L.P.; 328861 and 325040 to S.G.P.; and 312062 and 316820 to S.R.), Sigrid Juselius Foundation (grants to E.I., M.L., and S.R.), University of Helsinki (grant to K.K.; Faculty of Medicine early-career investigator grant to S.G.P.; HiLIFE Fellow grant to E.I.), Finnish Foundation for Cardiovascular Research to S.G.P. and S.R., University of Helsinki HiLIFE Fellow and Grand Challenge grants, H2020-INTERVENE (101016775 to S.R.), Fondation Leducq (grant 19CVD04 to E.I.), MIUR of Italy (project cod. PON03PE\_00060\_7, grant to CEINGE, G.F.), LENDULET-BIOMAG (grant 2018-342), H2020-discovAIR (874656), Chan Zuckerberg Initiative (seed networks for the HCA-DVP) to P.H., Ida Montin Foundation (grant to P.R.), Doctoral Programme in Population Health, University of Helsinki (grant to P.R.), Emil Aaltonen Foundation (grant to P.R.), and Business Finland Research-to-Business (1821/31/2021 to S.G.P.).

### AUTHOR CONTRIBUTIONS

S.G.P. and E.I. designed the study and developed the concept. S.G.P., I.B., K.K., I.H., and P.R. performed experiments. S.G.P., I.B., K.K., I.H., P.R., M.M.I., S.R., and E.I. analyzed data and interpreted results. A.K., M.D.D.T.,

A.S.d.F., G.F., J.K., and M.L. provided patient samples and clinical data. L.P. and P.H. established image analysis and processing tools. S.G.P. and E.I. wrote the manuscript. All authors reviewed and revised the manuscript.

### DECLARATION OF INTERESTS

A patent application covering the use of the here-suggested patient stratification methods has been filed (application: FI 20206284), in which University of Helsinki is the applicant and E.I. and S.G.P. are the inventors.

### INCLUSION AND DIVERSITY

We worked to ensure gender balance in the recruitment of human subjects. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.

Received: October 13, 2021  
Revised: November 26, 2021  
Accepted: January 18, 2022  
Published: February 8, 2022

### REFERENCES

- Abul-Husn, N.S., Manickam, K., Jones, L.K., Wright, E.A., Hartzel, D.N., Gonzaga-Jauregui, C., O'Dushlaine, C., Leader, J.B., Kirchner, H.L., Lindbuchler, D.M., et al. (2016). Genetic identification of familial hypercholesterolemia within a single U.S. health care system. *Science* 354, aaf7000.
- Benito-Vicente, A., Uribe, K.B., Jebari, S., Galicia-Garcia, U., Ostolaza, H., and Martin, C. (2018). Validation of LDLr activity as a tool to improve genetic diagnosis of familial hypercholesterolemia: a retrospective on functional characterization of LDLr variants. *Int. J. Mol. Sci.* 19, 1676.
- Borén, J., Chapman, M.J., Krauss, R.M., Packard, C.J., Bentzon, J.F., Binder, C.J., Daemen, M.J., Demer, L.L., Hegele, R.A., Nicholls, S.J., et al. (2020). Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur. Heart J.* <https://doi.org/10.1093/eurheartj/ehz962>.
- Borodulin, K., Tolonen, H., Jousilahti, P., Jula, A., Juolevi, A., Koskinen, S., Kuulasmaa, K., Laatikainen, T., Männistö, S., Peltonen, M., et al. (2018). Cohort profile: the national FINRISK study. *Int. J. Epidemiol.* 47, 696.
- Carpenter, A.E., Jones, T.R., Lamprecht, M.R., Clarke, C., Kang, I.H., Friman, O., Guertin, D.A., Chang, J.H., Lindquist, R.A., Moffat, J., et al. (2006). CellProfiler: image analysis software for identifying and quantifying cell phenotypes. *Genome Biol.* 7, R100.
- Chan, P., Jones, C., Lafrenière, R., and Parsons, H.G. (1997). Surface expression of low density lipoprotein receptor in EBV-transformed lymphocytes: characterization and use for studying familial hypercholesterolemia. *Atherosclerosis* 131, 149–160.
- Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 4.
- Consortium, T., Cardi, Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., Assimes, T.L., Thompson, J.R., Ingelsson, E., Saleheen, D., et al. (2013). Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat. Genet.* 45, 25–33.
- Gaddi, A., Arca, M., Ciarrocchi, A., Fazio, S., D'Alò, G., Tiozzo, R., Descovich, G.C., and Calandra, S. (1991). Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts. *Metabolism* 40, 1074–1078.
- Goldstein, J.L., Basu, S.K., and Brown, M.S. (1983). Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. *Meth. Enzymol.* 98, 241–260.
- Hagemenas, F.C., and Illingworth, D.R. (1989). Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia

- treated with lovastatin. *Arteriosclerosis: Official J. Am. Heart Assoc. Inc.* **9**, 355–361.
- Hagemenas, F.C., Pappu, A.S., and Illingworth, D.R. (1990). The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia. *Eur. J. Clin. Invest.* **20**, 150–157.
- Harris, C.R., et al. (2020). Array programming with NumPy. *Nature* **585**, 357–362.
- Homma, K., Homma, Y., Yoshida, T., Ozawa, H., Shiina, Y., Wakino, S., Hayashi, K., Itoh, H., and Hori, S. (2015). Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin. *J. Clin. Lipidol.* **9**, 210–216.
- Hunter, J.D. (2007). Matplotlib: a 2D graphics environment. *Comput. Sci. Eng.* **9**, 90–95.
- Ikonen, E. (2008). Cellular cholesterol trafficking and compartmentalization. *Nat. Rev. Mol. Cell Biol.* **9**, 125–138.
- Khera, A.V., Won, H.-H., Peloso, G.M., Lawson, K.S., Bartz, T.M., Deng, X., van Leeuwen, E.M., Natarajan, P., Erdem, C.A., Bick, A.G., et al. (2016). Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. *J. Am. Coll. Cardiol.* **67**, 2578–2589.
- Kirshner, H., Aguet, F., Sage, D., and Unser, M. (2013). 3-D PSF fitting for fluorescence microscopy: implementation and localization application. *J. Microsc.* **249**, 13–25.
- Klop, B., Elte, J.W.F., and Cabezas, M.C. (2013). Dyslipidemia in obesity: mechanisms and potential targets. *Nutrients* **5**, 1218–1240.
- Laakso, M., Kuusisto, J., Stančáková, A., Kuulasmaa, T., Pajukanta, P., Lusi, A.J., Collins, F.S., Mohlke, K.L., and Boehnke, M. (2017). The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. *J. Lipid Res.* **58**, 481–493.
- Laakso, M., Kuusisto, J., Stančáková, A., Kuulasmaa, T., Pajukanta, P., Lusi, A.J., Collins, F.S., Mohlke, K.L., and Boehnke, B. (2017). *Journal of Lipid Research* **58**, 481–493.
- Lahtinen, A.M., Havulinna, A.S., Jula, A., Salomaa, V., and Kontula, K. (2015). Prevalence and clinical correlates of familial hypercholesterolemia founder mutations in the general population. *Atherosclerosis* **238**, 64–69.
- Luo, J., Yang, H., and Song, B.-L. (2020). Mechanisms and regulation of cholesterol homeostasis. *Nat. Rev. Mol. Cell Biol.* **21**, 225–245.
- Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., Chapman, M.J., De Backer, G.G., Delgado, V., Ference, B.A., et al. (2019). 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Atherosclerosis* **290**, 140–205.
- Mamo, J.C.L., Watts, G.F., Barrett, P.H.R., Smith, D., James, A.P., and Pal, S. (2001). Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? *Am. J. Physiology-Endocrinology Metab.* **281**, E626–E632.
- McKinney, W. (2010). Data Structures for Statistical Computing in Python. Proceedings of the 9th Python in Science Conference. Scipy 2010.
- McQuin, C., Goodman, A., Chernyshev, V., Kamentsky, L., Cimini, B.A., Karhohs, K.W., Doan, M., Ding, L., Rafelski, S.M., Thirstrup, D., et al. (2018). CellProfiler 3.0: Next-generation image processing for biology. *PLOS Biology* **16**, e2005970.
- Pfisterer, S.G., Gateva, G., Horvath, P., Pirhonen, J., Salo, V.T., Karhinen, L., Varjosalo, M., Ryhänen, S.J., Lappalainen, P., and Ikonen, E. (2017). Role for formin-like 1-dependent actin-myosin assembly in lipid droplet dynamics and lipid storage. *Nat. Commun.* **8**, 14858.
- Piccaluga, P.P., Weber, A., Ambrosio, M.R., Ahmed, Y., and Leoncini, L. (2018). Epstein-barr virus-induced metabolic rearrangements in human B-Cell lymphomas. *Front Microbiol.* **9**.
- Raungaard, B., Brorholt-Petersen, J.U., Jensen, H.K., and Færgeman, O. (2000). Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia. *J. Clin. Pharmacol.* **40**, 421–429.
- Ray, K.K., Molemans, B., Schoonen, W.M., Giovias, P., Bray, S., Kiru, G., Murphy, J., Banach, M., De Servi, S., Gaita, D., et al. (2020). EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. *Eur. J. Prev. Cardiol.*
- Reynolds, S.C. (1985). A comparative microscopic and biochemical study of the uptake of fluorescent and 125I-labeled lipoproteins by skin fibroblasts, smooth muscle cells, and peritoneal macrophages in culture. *The American Journal of Pathology* **121**, 200–211.
- Ripatti, P., Rämö, J.T., Mars, N.J., Fu, Y., Lin, J., Söderlund, S., Benner, C., Surakka, I., Kiiskinen, T., Havulinna, A.S., et al. (2020). Polygenic hyperlipidemias and coronary artery disease risk. *Circ. Genomic Precision Med.* **13**, e002725.
- Romano, M., Di Taranto, M.D., D’Agostino, M.N., Marotta, G., Gentile, M., Abate, G., Mirabelli, P., Di Noto, R., Del Vecchio, L., Rubba, P., and Fortunato, G. (2010). Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy. *Atherosclerosis* **210**, 493–496.
- Romano, M., Di Taranto, M.D., Mirabelli, P., D’Agostino, M.N., Iannuzzi, A., Marotta, G., Gentile, M., Raia, M., Di Noto, R., Del Vecchio, L., et al. (2011). An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations. *J. Lipid Res.* **52**, 2095–2100.
- Sage, D., Donati, L., Soulez, F., Fortun, D., Schmit, G., Seitz, A., Guet, R., Vonesch, C., and Unser, M. (2017). DeconvolutionLab2: an open-source software for deconvolution microscopy. *Methods Image Process. Biologists* **115**, 28–41.
- Salo, V.T., Li, S., Vihinen, H., Hölttä-Vuori, M., Szkalitsy, A., Horvath, P., Belevich, I., Peränen, J., Thiele, C., Somerharju, P., et al. (2019). Seipin facilitates triglyceride flow to lipid droplet and counteracts droplet ripening via endoplasmic reticulum contact. *Developmental Cell* **50**, 478–493.e9.
- Schmitz, G., Brüning, T., Kovacs, E., and Barlage, S. (1993). Fluorescence flow cytometry of human leukocytes in the detection of LDL receptor defects in the differential diagnosis of hypercholesterolemia. *Arteriosclerosis Thromb. A J. Vasc. Biol.* **13**, 1053–1065.
- Snijder, B., Vladimer, G.I., Krall, N., Miura, K., Schmolke, A.-S., Kornauth, C., Lopez de la Fuente, O., Choi, H.-S., van der Kouwe, E., Gültekin, S., et al. (2017). Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. *Lancet Haematol.* **4**, e595–e606.
- Spandl, J., White, D.J., Psychl, J., and Thiele, C. (2009). Live cell multicolor imaging of lipid droplets with a new dye, LD540. *Traffic* **10**, 1579–1584.
- Stephan, Z.F., and Yurachek, E.C. (1993). Rapid fluorometric assay of LDL receptor activity by Dil-labeled LDL. *Journal of Lipid Research* **34**, 325–330.
- Sun, X.-M., Patel, D.D., Knight, B.L., and Soutar, A.K. (1998). Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. *Atherosclerosis* **136**, 175–185.
- Surakka, I., Horikoshi, M., Mägi, R., Sarin, A.-P., Mahajan, A., Lagou, V., Marullo, L., Ferreira, T., Miraglio, B., Timonen, S., et al. (2015). The impact of low-frequency and rare variants on lipid levels. *Nat. Genet.* **47**, 589–597.
- Tada, H., Kawashiri, M., Noguchi, T., Mori, M., Tsuchida, M., Takata, M., Nohara, A., Inazu, A., Kobayashi, J., Yachie, A., et al. (2009). A novel method for determining functional LDL receptor activity in familial hypercholesterolemia: application of the CD3/CD28 assay in lymphocytes. *Clinica Chim. Acta* **400**, 42–47.
- Talmud, P.J., Shah, S., Whittall, R., Futema, M., Howard, P., Cooper, J.A., Harrison, S.C., Li, K., Drenos, F., Karpe, F., et al. (2013). Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. *The Lancet* **381**, 1293–1301.
- Theirez, A., Blom, D.J., Ramin-Mangata, S., Blanchard, V., Croyal, M., Chemello, K., Nativel, B., Pichelin, M., Cariou, B., Bourane, S., et al. (2018). Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor). *Arteriosclerosis, Thromb. Vasc. Biol.* **38**, 592–598.

Urdal, P., Leren, T.P., Tonstad, S., Lund, P.K., and Ose, L. (1997). Flow cytometric measurement of low density lipoprotein receptor activity validated by DNA analysis in diagnosing heterozygous familial hypercholesterolemia. *Cytometry* *30*, 264–268.

Virtanen, P. (2020). SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nature Methods* *17*, 261–272.

Vanharanta, L., Peränen, J., Pfisterer, S.G., Enkavi, G., Vattulainen, I., and Ikonen, E. (2020). High-content imaging and structure-based predictions reveal functional differences between Niemann-Pick C1 variants. *Traffic* *21*, 386–397.

Vilhjálmsson, B.J., Yang, J., Finucane, H.K., Gusev, A., Lindström, S., Ripke, S., Genovese, G., Loh, P.-R., Bhatia, G., Do, R., et al. (2015). Modeling linkage

disequilibrium increases accuracy of polygenic risk scores. *Am. J. Hum. Genet.* *97*, 576–592.

Waskom, M., Botvinnik, O., O’Kane, D., Hobson, P., Lukauskas, S., Gemperline, D.C., Augspurger, T., Halchenko, Y., Cole, J.B., Warmenhoven, J., de Ruiter, J., Pye, C., Hoyer, S., Vanderplas, J., and Villalba, S. (2017). mwas-kom/seaborn: v0.8.1 (September 2017) (Zenodo). <https://doi.org/10.5281/zenodo.883859>.

Wiegman, A., Gidding, S.S., Watts, G.F., Chapman, M.J., Ginsberg, H.N., Cuchel, M., Ose, L., Aversa, M., Boileau, C., Borén, J., et al. (2015). Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur. Heart J.* *36*, 2425–2437.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Anti-LDLR mouse (clone 472413)	R&D Systems	Cat#MAB2148-100, Accession#P01130; RRID:AB_2135125
Anti-mouse Alexa Fluor 568	Fisher Scientific	Cat#A111004; RRID:AB_2534072
CD14 Monoclonal Antibody (Sa2-8), FITC,eBioscience™	Fisher Scientific	Cat#11-0141-82; RRID:AB_464949
CD3 Antibody anti-human, mouse monoclonal (BW264/56) APC conjugated	Miltenyi Biotec	Cat#130-113-687; RRID:AB_2726228
<b>Biological samples</b>		
Human plasma and buffy coat samples from anonymous healthy donors	Finnish Red Cross Blood Service	<a href="https://www.bloodservice.fi/">https://www.bloodservice.fi/</a>
Peripheral blood mononuclear cell (PBMC) samples from FINRISK 2012 population survey participants	Finnish institute of Health and Welfare (THL) Biobank	<a href="https://thl.fi/en/web/thl-biobank">https://thl.fi/en/web/thl-biobank</a>
Blood samples from heterozygous familial hypercholesterolemia (He-FH) patients in Metabolic Syndrome in Men study (METSIM)	<a href="#">Laakso et al., 2017</a>	Samples collected during follow-up
<b>Chemicals, peptides, and recombinant proteins</b>		
4,4-difluoro-2,3,5,6-bis-tetramethylene-4-bora-3a,4a-diaza-s-indacene (LD540)	Princeton BioMolecular Research ( <a href="#">Spandl et al., 2009</a> )	N/A
1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate (DiI)	Thermo Fisher	Cat#D282; LOT1801202
2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI)	Sigma-Aldrich	Cat#D9542
HCS CellMask™ Deep Red Stain	Thermo Fisher	Cat#H32721
HCS CellMask™ Green Stain	Thermo Fisher	Cat#H32714
LPDS (lipoprotein-deficient serum)	Prepared as described ( <a href="#">Goldstein et al., 1983</a> )	N/A
Low-density lipoprotein (LDL)	Prepared from human plasma as described ( <a href="#">Stephan and Yurachek, 1993</a> )	N/A
DiI-LDL	Prepared as described ( <a href="#">Reynolds, 1985</a> )	N/A
<b>Experimental models: Cell lines</b>		
EBV lymphoblasts	Coriell Cell Repository <a href="https://www.coriell.org/">https://www.coriell.org/</a>	Cat#GM14664
<b>Software and algorithms</b>		
Huygens Professional	Scientific Volume Imaging	<a href="https://svi.nl/Huygens-Professional">https://svi.nl/Huygens-Professional</a>
CellProfiler	<a href="#">McQuin et al., 2018</a>	<a href="https://cellprofiler.org/">https://cellprofiler.org/</a>
Pandas	<a href="#">McKinney, 2010</a>	<a href="https://pandas.pydata.org/">https://pandas.pydata.org/</a>
Numpy	<a href="#">Harris, 2020</a>	<a href="https://numpy.org/">https://numpy.org/</a>
Scipy	<a href="#">Virtanen, 2020</a>	<a href="https://scipy.org/">https://scipy.org/</a>
Python	Python Software Foundation	<a href="https://www.python.org/">https://www.python.org/</a>
Lipidalyzer	<a href="#">Salo et al. (2019)</a>	<a href="https://bitbucket.org/szkabel/lipidalyzer/get/master.zip">https://bitbucket.org/szkabel/lipidalyzer/get/master.zip</a>
Python tools to process imaging data collected with Opera Phenix	This study	<a href="https://doi.org/10.5281/zenodo.5807656">https://doi.org/10.5281/zenodo.5807656</a>
Matplotlib	<a href="#">Hunter (2007)</a>	<a href="https://matplotlib.org/">https://matplotlib.org/</a>
MATLAB	MathWorks	<a href="https://www.mathworks.com/products/matlab.html">https://www.mathworks.com/products/matlab.html</a>
Seaborn	<a href="#">Waskom et al. (2017)</a>	<a href="https://seaborn.pydata.org">https://seaborn.pydata.org</a>



### RESOURCE AVAILABILITY

#### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Simon Pfisterer ([simon.pfisterer@helsinki.fi](mailto:simon.pfisterer@helsinki.fi))

#### Materials availability

This study did not generate new unique reagents.

#### Data and code availability

- The authors declare that the data supporting the findings of this study are available within the paper and its supplemental information files. Genetic data and laboratory values for the subjects of the FINRISK cohort study are available from the THL Biobank (<https://thl.fi/en/web/thl-biobank>).
- Custom python tools for image processing and deconvolution can be accessed via: <https://doi.org/10.5281/zenodo.5807656>. Software tools for lipid droplet detection have been described previously (Salo et al., 2019). The details are also listed in the [key resources table](#).
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

#### Human subject samples

All blood samples were collected in accordance with the declaration of Helsinki regarding experiments involving humans. He-FH patients were identified in the Metabolic Syndrome in Men study (METSIM) (Laakso et al., 2017), which was approved by the ethics committee of the Kuopio University Hospital on December 20, 2004 (number 171/2004) All samples from the METSIM study are from male subjects. Two He-FH patients (male and female) (Cys325Tyr and Ser580Phe) for which we obtained PBMC and EBV lymphoblast samples were described previously (Romano et al., 2011) and were retrieved from the CEINGE Biobank which received approval from the ethical committee of the Università degli Studi di Napoli Federico II (Number 157/13, September 9, 2013). PBMC samples from the Finnish population survey, FINRISK 2012, and the donor linked data (including genotypes) were obtained from THL Biobank ([www.thl.fi/biobank](http://www.thl.fi/biobank)) and used under the Biobank agreements no 2016\_15, 2016\_117 and 2018\_15. Blood samples were collected from the voluntary donors of the FINRISK 2012 population cohort with written consent permitted by the ethical committee of the Hospital District of Helsinki and Uusimaa (permit 162/13/03/00/2011). The FINRISK 2012 study groups consisting of donors with elevated LDL-c levels (LDL > 5 mM, hLDL-c) and normal levels (LDL-c 2.0–2.5 mM, nLDL-c) were age, gender (20 male, 20 female, with one male sample not successfully recovered) and BMI matched. The donors in neither of the groups had cholesterol lowering medication by the time of sampling, and based on a food frequency questionnaire, did not receive an elevated proportion of energy intake as saturated or trans-fat. Buffy coat samples from healthy blood donors were obtained from the Finnish Red Cross (permit 392016) (gender information not available). Three healthy volunteers (two male, one female) donated blood samples on two consecutive days after overnight fasting, to assess the intraindividual variation of LDL uptake and lipid mobilization. The METSIM cohort subjects are described in [Table S1](#) and FINRISK cohort subjects in [Table S2](#).

#### Cell lines

Control EBV lymphoblasts (GM14664) were obtained from Coriell Cell Repository and cultured in RPMI-1640 supplemented with 15% FBS, penicillin/streptomycin (100 U/ml each) and 2 mM L-Glutamine. For continuous culturing of EBV lymphoblasts,  $3 \times 10^6$  cells were transferred to 5 mL of fresh medium once a week. Cells were cryopreserved in 70% PBMC medium (RPMI-1640, penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1 mM HEPES), 20% FBS and 10% DMSO.

### METHOD DETAILS

#### PBMC isolation

Blood or buffy coat samples were mixed 1:1 with phosphate buffered saline (PBS) including 2.5 mM EDTA (PBS-E). The blood mixture was gently layered over Histopaque Premium (1.073, for mononuclear cells) and centrifuged 40 min at 400 g. The PBMC cell layer was removed, transferred to a new 15 mL reaction tube and mixed with PBS-E. Cells were centrifuged at 400 g for 10 min and incubated in 2 mL of red blood cell lysis buffer for 1 minute (155 mM  $\text{NH}_4\text{Cl}$ , 12 mM  $\text{NaHCO}_3$ , 0.1 mM EDTA). 10 mL of PBS-E was added and cells were pelleted and washed with PBS-E. Then cells were resuspended in 5 mL PBMC medium (RPMI-1640, penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1 mM HEPES), counted, pelleted and cryopreserved.

### Cell treatments, Dil-LDL uptake, transfer to imaging plates and fixation

Cryopreserved EBV lymphoblasts or PBMCs were thawed in PBMC medium, and centrifuged at 400 g for 10 min. The cells were resuspended in PBMC medium and transferred to a well of a 96 well plate (200,000 cells per well), containing FBS (10% final concentration) or LPDS (5% final concentration) and incubated for 24 h (prepared as described [Goldstein et al., 1983]). Cells were then incubated with freshly thawed Dil-LDL at 30  $\mu\text{g}/\text{mL}$  final concentration for 1 h at 37°C (prepared as described [Reynolds, 1985; Stephan and Yurachek, 1993]), which yielded an optimal signal intensity at a linear detection range in PBMCs. Subsequently, cells were transferred to conical 96 well plates and centrifuged at 400 g for 10 min. Using a robotic platform (Opentrons, New York, USA) medium was removed and cells were resuspended in PBMC medium. Cells were centrifuged, automatically resuspended in PBMC medium and transferred to PDL coated 384 well high-content imaging plates (approximately 40 000 cells/well, a density where individual cells are not on top but close to each other). The robotic resuspension ensured homogenous cell adhesion to the imaging plates. After 30 min of incubation at 37°C cells were automatically fixed with 4% paraformaldehyde in 250 mM HEPES, 1 mM  $\text{CaCl}_2$ , 100  $\mu\text{M}$   $\text{MgCl}_2$ , pH 7.4 and washed with PBS. For lipid droplet and LDLR surface stainings, cells were directly transferred to PDL coated 384 well high-content plates, adhered, automatically fixed and washed with PBS.

### Lipid droplet analyses

Cells were processed as described before (Pfisterer et al., 2017) with the following changes: Fixed cell samples were automatically stained with 1  $\mu\text{g}/\text{ml}$  LD540 (Princeton BioMolecular Research, (Spandl et al., 2009)) and 5  $\mu\text{g}/\text{ml}$  DAPI. 3D stacks of optical slices were acquired automatically either with a Nikon Eclipse Ti-E inverted microscope equipped with a 40  $\times$  Planfluor objective with NA 0.75 and 1.5 zoom; duplicate wells, each with six image fields per patient, or with a PerkinElmer Opera Phenix High Content Imaging system with a 63x water immersion objective, NA 1.15; duplicate wells, each with 14, 16 (two wells combined) or 24 (two wells combined) image fields. Image stacks were automatically deconvolved either with Huygens software (Scientific Volume Imaging, b.v.) or a custom-made Python tool based on the open-source tools PSF generator (Kirshner et al., 2013) and deconvolution lab (Sage et al., 2017). Maximum intensity projections were made from the deconvolved image stacks with custom Python tools. Automated quantification of lipid droplets was performed as described previously (Pfisterer et al., 2017; Salo et al., 2019; Vanharanta et al., 2020).

### LDLR surface staining

All staining procedures were performed automatically. Fixed cells were quenched with 50 mM  $\text{NH}_4\text{Cl}$  for 15 min and washed twice with PBS. Cells were incubated with block solution (PBS, 1% BSA) for 10 min followed by staining with mouse anti-LDLR in block solution for 60 min. Cells were washed three times with PBS followed by incubation with secondary antibody solution (anti-mouse-Alexa 568, DAPI 5  $\mu\text{g}/\text{ml}$  and HCS CellMask Green stain 0.25  $\mu\text{g}/\text{ml}$ ) for 45 min at room temperature. Cells were washed with PBS and 3D stacks of optical slices were acquired for DAPI (nuclei), CellMask Green (cytoplasm), Alexa 568 (LDLR surface) and Alexa 640 (background) channels using an Opera Phenix high-content imaging system with a 40x water immersion objective NA 1.1; quadruplicate wells, each with seven image fields per patient. LDLR surface and background images were automatically deconvolved with our custom build Python deconvolution tools and maximum intensity projections were made. The resulting images were automatically analysed with CellProfiler (Carpenter et al., 2006; McQuin et al., 2018). LDLR surface intensities were background subtracted for each individual cell and normalized by subtracting mean LDLR surface intensities from the two controls, which were included in each imaging plate.

### Quantification of Dil-LDL uptake

Dil-LDL labeled, and fixed cells (see “cell treatments”) were automatically processed with a robotic platform (Opentrons). Cells were stained with 5  $\mu\text{g}/\text{ml}$  DAPI and 0.5  $\mu\text{g}/\text{ml}$  HCS CellMask Deep Red and image stacks for three channels, DAPI (nuclei), Dil-LDL and CellMask Deep Red (cytoplasm) were acquired. Automated microscopy and single cell quantifications with CellProfiler were performed as described in the section LDLR surface staining; Quadruplicate wells, each with 7 image fields for heterozygous FH patients; duplicate wells, each with 13 image fields for FINRISK subjects. Plate effects were determined with control samples and corrected for in the individual experiments.

### LDL-c polygenic risk score (LDL-PRS)

Genotyping of FINRISK2012 samples has been previously described (Ripatti et al., 2020) We calculated three PRSs for LDL: 1) the previously published PRS by Talmud et al. with 12 LDL-increasing alleles, 2) a genome-wide PRS with 6376447 variants using the recent LDpred method, and 3) a PRS s combining 1) and 2) (Talmud et al., 2013; Vilhjálmsón et al., 2015). The PRSs were calculated as the sum of the risk alleles weighted by their effect sizes. The weights for Talmud’s PRS were based on the original publication (Talmud et al., 2013). The weights for the LDpred lipid PRSs were based on a custom-run European genome-wide association study (GWAS) meta-analysis with 56945 samples excluding the FINRISK samples to eliminate sample overlap (Surakka et al., 2015). The LDpred method is a Bayesian approach to calculate a posterior mean effect size for each variant based on a prior of effect size and linkage disequilibrium (a measure of how much a variant correlates with other variants) (Vilhjálmsón et al., 2015). Whole-genome sequences from 2690 Finns served as the linkage disequilibrium reference population for LDpred. LDpred requires a tuning parameter  $\rho$  representing the fraction of causal variants in a given phenotype. We used  $\rho$  of 0.01 as it provided the highest  $r^2$  in 4697 gen-

otyped Finnish samples from the independent GeneRISK cohort. GeneRISK is an ongoing prospective observational study including randomly selected 45-65 year old individuals from Southern Finland (<https://thl.fi/en/web/thl-biobank/for-researchers/sample-collections/generisk-study>), with the genetic risk loci based on (Consortium et al., 2013). A total of 4697 GeneRISK samples were genotyped using the HumanCoreExome BeadChip. Genotypes were called together with other available data sets using zCall at FIMM. QC and imputation were performed in the same manner as for the FINRISK samples. The PRSs were calculated using PLINK 2.0 Alpha 1 (Chang et al., 2015). As the 12 variants included in Talmud's PRS were also included in the LDpred LDL-c PRS, we accounted for variant overlap by estimating the relative contributions of the two PRSs using linear regression with both PRSs (standardised) in a single model in the GeneRISK cohort. We combined the PRSs by weighting them by their regression coefficients and subsequently summing them together for each individual. With the combined PRS, we were not only able to account for variant overlap between the PRSs, but also address LDpred's tendency to dilute the effects of high-impact SNPs, as well as catch the non-linear contributions of the different APOE haplotypes to lipid levels (Talmud et al., 2013; Vilhjálmsson et al., 2015). We used the combined PRS in all subsequent analyses. A comparison of the different PRSs and their performance in the entire FINRISK cohort is described in Table S3. LDL uptake and lipid mobilization parameters were normalized to a range from 0 to 1 to generate uptake and mobilization scores. Hybrid scores represent the average of LDL-PRS and uptake and/or mobilization scores which were normalized to a range from 0 to 1.

### QUANTIFICATION AND STATISTICAL ANALYSIS

Segmented images from CellProfiler underwent routine visual controls to verify cell identification and filter out potential imaging artifacts. Then, lymphocytes and monocytes were detected based on the size of the cytoplasm ( $L_y < 115 \mu\text{m}^2$ ,  $M_o > 115 \mu\text{m}^2$ ) (See Figure S1). We averaged the cellular mean Dil-LDL intensities and organelle counts for each cell population and well and normalized them to the average of both controls included in each plate, set to 100%. For LD quantifications we first selected monocytes with at least one LD. We then averaged cellular LD number and total LD area (LD number x LD size) for each well. For lipid mobilization we first averaged the control medium results for LD-Pos, LD-No, and LD-area from duplicate wells and then divided these by the respective per well results after lipid starvation. We used Python (Python Software Foundation, [www.python.org](http://www.python.org)) with the following packages to perform the single cell data analysis (Pandas [McKinney, 2010], Numpy [Harris, 2020], Scipy [Virtanen, 2020], Matplotlib [Hunter, 2007], Seaborn [Waskom et al., 2017]). For statistical significance testing we utilized aggregated single cell data at the level of individual wells ( $n$  = number of wells per treatment and patient). First, we performed Levene's test to assess the equality of sample variation. For equal sample amounts and variance, we carried out a two-tailed Student's t-test. For unequal samples or variance, we utilized Welch's t-test. For correlations we first performed a linear regression of the two measurements and then calculated a two-sided p-value for a hypothesis test whose null hypothesis is that the slope is zero, using Wald Test with t-distribution of the test statistic. Fisher's exact probability test was used to calculate the odds ratio. Among the FINRISK2012 hLDL-c subgroup there is one individual with a serum LDL-c of 10.1 mmol/l. We performed a sensitivity analysis by removing this subject from our analysis, to verify that the major conclusions of this study are not affected by this individual.